Deuterium Depletion in Life Science




Depletion of body deuterium (D) can simply be achieved by consumption or prolonged administration of deuterium-depleted water (DDW) and nutrients deficient in D. It was therefore postulated that D-depletion would have therapeutic use in patients with cancer and other neoplastic diseases. In subsequent toxicology studies DDW appeared to be completely safe and non-toxic when given to mice in place of regular water for several months. Following preclinical safety and efficacy studies, a Phase II double blind randomized clinical trial was initiated to evaluate the potential usefulness of therapeutic efficacy and safety of DDW in patients with prostate tumor.


3rd International Congress on Deuterium Depletion


The 3rd International Congress on Deuterium Depletion was held on 7-8 May 2015 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and mental diseases. The conference's goal was to provide a scientific forum for all stakeholders of this field of science and enable the interactive exchange of state-of-the-art knowledge.

At the 3rd International Congress on Deuterium Depletion leading scientists from seven countries (USA, France, Spain, United Kingdom, Russia, Sweden, Hungary) presented and discussed current advances in the research and various application of deuterium depletion. Further to its scientific content, 3rd International Congress on Deuterium Depletion was a networking event, a unique opportunity to meet all the stakeholders of deuterium depletion. Initiation of cross-border co-operations between scientists and institutions was also facilitated during the conference.


Official homepage:

Please fill in your email in order to receive the HYD newsletter.

HYD Pharma Receives Ethical Approval for Phase 2 Clinical Trial Investigating the Anticancer Effect of Deuterium Depletion in CL 2016. 07. 18.

HYD Pharma Inc. has been granted ethical approval by the State Institute for Drug Control (SIDC) in Slovakia for Phase 2 as one-of-the-first clinical trials to prove the anticancer effect of deuterium-depleted water (DDW) in chronic lymphocytic leukemia (CLL).